glp-1 news 2025 november Receptor Agonist Market Valued at USD 62.86 Billion in 2025, Set to Grow at 17.5% CAGR Through 2034 GLP-1 RA prescription trends: January

Make sure your chart accurately reflects all weight-related health conditions

Youll know whether you tolerate these medications well, how much appetite suppression you experience, and what kind of weight loss pace to expect

Many notice more consistent results after titration as the dose increases

The FXR-activating function of GLP-1RAs also helps protect the gut barrier (Sorribas et al., 2019)

Remaining Scope for Side-Effect Improvement Retatrutide is a triple-action therapy that, like Lillys Mounjaro and Zepbound drugs, targets glucagon-like peptide-1, or GLP-1, and glucose-dependent insulinotropic polypeptide, or GIP, while also acting on the glucagon receptor

Insulin degludec/liraglutide: a review in type 2 diabetes